Gore Viatorr TIPS Endoprosthesis
by W. L. Gore & Associates, Inc.
PMA P040027510(k) K024178
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA PMA PMA | NumberP040027 | Date6 Dec 2004 | StatusActive |
| United States | FDA 510(k)SESE 510(k) | NumberK024178 | Date7 Mar 2003 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k), FDA PMA Active
Specification
- Trade name
- Gore Viatorr Tips
- Generic name
- SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS
- PMA number
- 510(k) Number
- FDA product code
- JCT
- Device class
- Class II
- Regulation
- 21 CFR Part 878.3720
- Advisory committee
- General, Plastic Surgery
- FDA decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 18 Sep 2026
The Gore Viatorr TIPS Endoprosthesis is a portosystemic shunt designed to manage portal hypertension and its related clinical complications. It is indicated for use in both de novo and revision treatments for conditions including variceal bleeding, gastropathy, ascites, and hepatic hydrothorax.
This device is manufactured by W. L. Gore & Associates and has received FDA PMA and 510(k) authorizations. It is intended for clinical use in the treatment of specific hepatic conditions as defined by its regulatory indications.
Other devices from W. L. Gore & Associates, Inc.
Questions
AI-generated answers, 18 Sep 2026
What is the Gore Viatorr TIPS Endoprosthesis used for?
The device is indicated for the de novo and revision treatment of portal hypertension and its complications, which include variceal bleeding, gastropathy, ascites, and hepatic hydrothorax.
Who manufactures the Viatorr Endoprosthesis?
The device is manufactured by W. L. Gore & Associates, Inc., based in Flagstaff, Arizona.
Is the Gore Viatorr TIPS Endoprosthesis FDA authorized?
Yes, the device has received both FDA 510(k) and PMA authorizations for its indicated use in treating portal hypertension.